Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement

Podobne knjige/članki

• Emicizumab, the factor VIII mimetic bispecific monoclonal antibody: effects on thrombin generation and thromboelastometry
  od: Armando Tripodi, et al.
  Izdano: (2025-11-01)
• Autoimmune hemophilia at rescue
  od: Mannucci, Pier Mannuccio, et al.
  Izdano: (2009)
• Factor VIII inhibitor and source of replacement therapy
  od: Mannucci, Pier Mannuccio, et al.
  Izdano: (2012)
• Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
  od: Jonsson, Fredrik, et al.
  Izdano: (2021)
• Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays
  od: Kizilocak, Hande, et al.
  Izdano: (2019)